Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 759-765

  Copelan, E A ^a   Ceselski, S K ^a   Ezzone, S A ^a   Lasky, L C ^a   Penza, S L ^a   Bechtel, T P ^a   Klein, J L ^a   Hehmeyer, D M ^a   Scholl, M D ^a   Marshall, D D ^a   Elder, P J ^a   Risley, G L ^a   Avalos, B R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; COLONY FORMING UNIT; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC CELL; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL;

EID: 0031026807     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.759     Document Type: Article

References (36)

1. To LB, Roberts MM, Haylock DN, et al.: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277-284, 1992
2. Sheridan WP, Begley CG, Juttner CA, et al.: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
3. Bensinger W, Singer J, Appelbaum F, et al.: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158-3163, 1993
4. Pettengell R, Morgenstern GR, Woll PJ, et al.: Peripheral blood cell transplantation in lymphoma and leukemia using a single apheresis. Blood 82:3770-3777, 1993
5. Chao NJ, Schriber JR, Grimes K, et al.: Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031-2035, 1993
6. Rosenfeld CS, Gremba C, Shadduck RK, et al.: Engraftment with peripheral blood stem cells using non-controlled rate cyropreservation: Comparison with autologous marrow transplantation. Exp Hematol 22:290-194, 1994
7. Craig JIO, Anthony RS, Stewart A, et al.: Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Hematol 85:210-212, 1993
8. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74:1905-1914, 1989
9. Boiron J-M, Marit G, Fabéres C, et al.: Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 12:49-55, 1993
10. Siena S, Bregni M, Bonsi L, et al.: Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 21:1583-1590, 1993
11. Goldberg MA, Antin JH, Guinan EC, et al.: Cyclophosphamide cardiotoxicity: Analysis of dosing as a risk factor. Blood 5:1114-1118, 1986
12. Lieberg CF, Rausing A, Langeland P: Cyclophosphamide hemorrhagic cystitis. Scand J Urol Nephrol 4:183-190, 1970
13. Clelland BD, Pokorny CS: Cyclophosphamide related hepatotoxicity. Aust NZ J Med 23:408, 1993
14. Kaldor JM, Day NE, Pettersson F, et al.: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1-6, 1990
15. VanMaanen JMS, Retel J, DeVries J, Pinedo HM: Mechanism of action of antitumor drug etoposide: A review. J Natl Cancer Inst 80:1526-1533, 1988
16. Postmus PE, Mulder NH, Sleijfer DT, et al.: High-dose etoposide for refractory malignancies: A phase I study. Cancer Treat Rep 68:1471-1474, 1984
17. Gianni AM, Bregni M, Siena S, et al.: Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 10:1955-1962, 1992
18. Brown RA, Herzig RH, Wolff SN, et al.: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473-479, 1990
19. Herzig RH: High-dose etoposide and marrow transplantation. Cancer 67:292-298, 1991 (suppl 1)
20. Aisner J, Lee EJ: Etoposide, current and future status. Cancer 67:215-218, 1991 (suppl 1)
21. Bezwoda WR, Seymour L, Ariad S: High dose etoposide in treatment of metastatic breast cancer. Oncology 183:104-107, 1991
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Cox DR: Regression models and life tables. J R Stat Soc [B] 34:187-202, 1972
24. Rustagi JS: Rowman and Allanheld Probability and Statistics Series - Introduction to Statistical Methods, vol 1. Totowa, NJ, Littlefield Adams, 1984, pp 195-232
25. Bregni M, Siena S, DiNicola M, et al.: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
26. Gianni AM, Bregni M, Siena S, et al.: Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8:768-778, 1990
27. Pui CH, Ribeiro RC, Hancock ML, et al.: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
28. Rosenfeld CS, Shadduck RK, Zeigler ZR, et al.: Cyclophosphamide-mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant 15:433-438, 1995
29. To LB, Shepherd KM, Haylock DN, et al.: Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18:442-447, 1990
30. Jagannath S, Vesole DH, Glenn L, et al.: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1660-1672, 1992
31. Antman K, Ayash L, Elias K, et al.: A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102-110, 1992
32. Philip T, Guglielmi PT, Chauvin F, et al.: Autologous bone marrow transplantation versus conventional chemotherapy in relapsed non-Hodgkin's lymphoma: Final analysis of the PARMA randomized study (216 patients). Proc Am Soc Clin Oncol 14:390a, 1995 (abstr)
33. Jones RJ, Piantadose S, Mann RB, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527-537, 1990
34. Haas R, Möhle R, Frühauf S, et al.: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-1794, 1994
35. Chabannon C, Le Coroller A-G, Faucher C, et al.: Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 4:171-179, 1995
36. Dreger P, Kloss M, Petersen B, et al.: Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86:3970-3978, 1995